Blog
Get the latest news about liver diseases and more
Get the latest news about liver diseases and more
A study shows spironolactone reduces fatty liver risk in patients with hypertension, lowering liver fat accumulation and slowing fibrosis progression.
Autoimmune hepatitis incidence has increased notably in older adults, with higher prevalence and better treatment response, often presenting with milder symptoms.
A study shows that eating fewer than three times a day and fasting over 14 hours increases fatty liver risk due to circadian rhythm disruption.
A study published analyzes the effectiveness of a low-carbohydrate diet in patients with fatty liver disease. Results show weight loss, reduced abdominal circumference, and improvements in liver inflammation and glucose metabolism.
Orforglipron, an oral GLP-1 small molecule, shows significant weight loss results and may become an alternative to injectable drugs like Ozempic or Wegovy.
Hydronidone has demonstrated significant reversal of liver fibrosis in patients with chronic hepatitis B, offering a potential new therapeutic option.
HU6 is a novel oral drug that reduces liver fat and body weight through controlled metabolic acceleration, showing promising results in clinical trials compared to placebo.
A large study shows that daily alcohol consumption, even in small amounts, worsens liver fibrosis in patients with metabolic liver disease.
2 de October de 2018
3 de June de 2021
18 de December de 2022
Hepatitis E is an acute inflammatory disease of the liver that can lead to fulminant hepatitis.
It is the second cause of liver transplantation in the USA and in the next 10 years is expected to be the first cause. It is a serious illness if it is not treated properly.
Hepatitis A is an acute inflammatory disease of the liver, caused by infection with hepatitis A virus (VAH).